| dc.contributor.author | Caiado, A | |
| dc.contributor.author | Antunes, M | |
| dc.contributor.author | Santos, AL | |
| dc.contributor.author | Esteves, J | |
| dc.contributor.author | Diniz, MJ | |
| dc.date.accessioned | 2013-12-03T15:34:32Z | |
| dc.date.available | 2013-12-03T15:34:32Z | |
| dc.date.issued | 2012 | |
| dc.description.abstract | Introduction: Hepatitis C virus (HCV) infection in patients with hereditary bleeding disorders (HBDs), as a consequence of treatment with transfusion of human bloodderived components between the late 1970s and 1980s, represents a major health concern. Objectives: Assessment and evaluation of the burden of HCV infection, its complications, and treatment in a population of patients with HBDs. Methods: Analysis of a series of 161 patients with HBDs treated in the Immunohemotherapy Service of the Centro Hospitalar de Lisboa Central (Lisboa, Portugal), consultation and systematic review of the patients clinical processes, elaboration of a database comprising the information gathered; and statistical study of its variables: age, gender, degree of severity of the bleeding disorder, treatment modality, and major and minor complications of HCV infection. Results: Sixty-five (40%) of the 161 patients have HCV infection. Among the patients with hemophilia A, 36% are severe and 62% of those have HCV infection; 9% moderate with 57%; 25% mild with 20%. In the hemophilia B group, 8% are severe with 23% infected and 6% moderate or mild with 10%. Concerning the patients with von Willebrand disease, 12% have type 2 with 16% infected and 4% have type 3 with 86%. Conclusions: HCV infection represents a very significant complication of the treatment employed in the past in the studied population. Considering that most of these patients were infected in the late 1970s and early 1980s, and the natural evolution of HCV infection in patients without bleeding disorders, it is expected that the prevalence of major complications will rise significantly in the coming years. Prophylactic measures should be implemented to enhance the follow-up protocols and prevent further development of liver damage in these patients. | por |
| dc.identifier.citation | World Federation of Hemophilia World Congress; 2012, 8 a12 Jul. Paris, França | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/1575 | |
| dc.language.iso | eng | por |
| dc.peerreviewed | yes | por |
| dc.publisher | Serviço de Imuno-Hemoterapia do Hospital de S. José, Centro Hospitalar de Lisboa Central, EPE | por |
| dc.subject | HSJ IMU | por |
| dc.subject | HCV | por |
| dc.subject | Hemorragia | por |
| dc.subject | Infecção | por |
| dc.subject | Doenças Hereditárias | por |
| dc.title | HCV Infection in Patients with Hereditary Bleeding Disorders | por |
| dc.type | other | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess | por |
| rcaap.type | other | por |
